One-Liner
A free consumer smartphone app in Latin America that compares a purchased generic medication's appearance against the manufacturer's published reference images to flag visual mismatches.
AI Thinking Process
Consumer quota: LatAm smartphone camera + multimodal AI for visual authentication of off-patent generic medications at independent pharmacies. Counterfeit generics are a real LatAm consumer problem.
Sproxil (Africa/Asia, not LatAm), Authentic Vision (enterprise brand-side), TruScan ($5K hardware spectroscopy). LatAm consumer phone-camera verification gap appears real.
G009 Accuracy Cliff fires HARD. Tool says 'looks real,' it's a counterfeit that injures patient — catastrophic liability. Phone-camera cannot deliver near-100% accuracy bar.
Pivot: 'match not authenticate' — does this drug appearance match manufacturer reference? Mismatch flags for pharmacy check; does NOT claim authenticity.
Survived Pass 1 at 36% conviction (relaxed threshold). Biggest worry: G009 accuracy cliff even with match framing. Emerging market, consumer, new category.
Sproxil confirmed: Nigeria, Mali, Ghana, Tanzania, Kenya, India, Pakistan only. No LatAm presence. BUT: Sproxil is the natural LatAm expansion candidate — window is 12-24 months before they enter.
Conviction 36% → 30%. G009 accuracy liability combined with Sproxil-expansion overhang and weak consumer freemium unit economics.
Killed in deepening: G009 accuracy liability cliff + Sproxil natural expansion window 12-24 months + consumer freemium unit economics insufficient to sustain the accuracy investment required.
Kill Reason
The accuracy cliff is fatal: even with careful 'match not authenticate' framing, a wrong call on pharmaceutical safety has catastrophic liability exposure. Sproxil, the African drug authentication leader, has no LatAm presence — but their natural LatAm expansion would eliminate the market gap in 12-24 months. Consumer freemium unit economics are too weak to sustain the accuracy investment required.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: The FDA FAERS database is public and already analyzed by multiple academic and consumer health tools. The product's differentiation would need to be clinical interpretation of adverse events — which requires medical supervision to publish actionable advice without running into FDA's off-label promotion rules. Revenue model is unclear: consumers don't pay for health data tools at sustainable ARPU, and pharma companies would not pay for a tool that highlights their drug's adverse events.
killed: FEATURE gate killed it in Pass 2. Every major biologic drug manufacturer launches a branded patient-support app alongside PDUFA approval (BiogenLink for MS, MyOcrevus for Ocrevus, Complete for Humira for arthritis). Eisai/Biogen will almost certainly launch a LEQEMBI patient-support app at the August 24 approval event. An independent app loses the primary acquisition channel — physicians and specialty pharmacies push the branded app — and cannot close the acquisition-cost math against a free branded competitor.
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.